Former evidence delineates a strong correlation between cancer and venous thromboembolic events (VTEs). Of all the malignancies, pancreatic cancer confers the highest risk for developing VTE during the course of the disease. The role of primary thromboprophylaxis in the comprehensive treatment of pancreatic cancer remains unclear. We have conducted a systematic review to assess the role of primary thromboprophylaxis in pancreatic cancer. Literature searches included PUBMED, EMBASE, Cochrane Library, and the database of clinical trials in order to identify relevant publications. Seven publications that included 6,003 patients were analyzed in our systematic review. The systematic review of current literature indicates that thromboprophylaxis reduces the risk of VTE without increasing the risk of major bleeding. However, data regarding survival benefits are inconclusive.
Introduction
Cancer is highly associated with increased risk for venous thromboembolic event (VTE), as reported first by Trousseau >150 years ago. 1 Furthermore, various studies have demonstrated that cancer augments VTE risk by sevenfold, with pancreatic cancer (PC) being an additional risk factor. 2, 3 Sproul et al were the first to report a relationship between PC and thrombosis, documenting a 60% prevalence of venous thrombosis during autopsy, compared to 20%-25% in other malignancies. It has been suggested that the risk of VTE is closely related to the tumor biology, in terms of not only the metastatic course but also tumor grade and proliferation index. Of all the solid tumors, the highest rate of VTE has been noted in PC, while the prevalence of VTE ranges from 4.1% to 12.1% in different trials. [4] [5] [6] The majority of patients with PC are diagnosed with metastatic disease. The presence of metastatic disease is strongly associated with an increased risk for VTE. An analysis of the data in the California Cancer Registry demonstrates that regardless of cancer type, the incidence of VTE is higher in patients with metastatic disease at the time of diagnosis.
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Perl et al thrombosis, portal or superior mesenteric vein thrombosis, spontaneous arterial thromboembolism, extremity ischemia, and mesenteric or iliofemoral occlusion. [8] [9] [10] [11] Cancer therapy (surgery, chemotherapy, and hormonal therapy) serves as an additional risk factor for developing VTE. According to a retrospective analysis of the Prophylaxis of Thromboembolism During Chemotherapy (PROTECHT) study, 12 in the absence of thrombophylaxis, the highest risk of thrombosis is seen in patients receiving gemcitabine (8.1%) or cisplatin-based chemotherapy (7%). The combination of both drugs increased the risk to up to 10%. Because gemcitabine represents a major therapeutic alternative in PC, it may induce further risk for VTE. 12 According to the MicroTec study, 13 circulating tissue factor-bearing microparticles are associated with a higher risk of VTE. Thromboprophylaxis with low-molecular-weight heparin (LMWH) in patients with high levels of tissue factorbearing microparticles significantly reduces VTE. 13 In addition to chemotherapy, supportive care measures used in cancer patients may enhance the risk of VTE. The use of colony-stimulating hormones such as erythropoietin for treating symptomatic anemia has been associated with an increased risk of VTE. A meta-analysis of 35 studies reported that the use of epoetin or darbepoetin increases the risk of TEs by ~67% compared to patients not receiving these agents. 14 Sorensen et al 15 have reported an inferior overall survival in patients with cancer and VTE. This finding has been further confirmed in PC, which is associated with a diminished overall survival when diagnosed synchronous with VTE. The overall survival is even worse when the VTE occurs during the course of chemotherapy. 15 Several studies have evaluated the efficacy and safety of LMWH as primary thromboprophylaxis for VTE in cancer patients, indicating contradictory results. Prophylaxis was associated with a statistically significant reduction of TEs; however, survival benefit was not documented. Therefore, most current guidelines do not endorse the routine use of thromboprophylaxis. Nevertheless, some guidelines do support considering primary thromboprophylaxis on a case-by-case basis in highly selected outpatients with solid tumors receiving chemotherapy. 16 The rationale for incorporating LMWH into practice originates not only from the antithrombotic prospect but also from the putative antineoplastic traits of these drugs. It has been shown that patients treated with long-term anticoagulant therapy have a relatively low incidence of cancer. [17] [18] [19] A few reports have demonstrated tumor regression, suggesting the potential for antineoplastic activity of LMWH. [20] [21] [22] Therefore, LMWH has been adopted as a favorable anticoagulant in cancer patients with VTE.
Methods
Data sources
We 
Results and discussion
Thrombophylaxis in PC Key clinical trials
The characteristics of the randomized controlled trials (RCTs) that enroll PC patients for primary thrombophylaxis (as the target population or partially) are presented in Table 1 .
LMWH as primary thrombophylaxis in PC
Several RCTs have appraised primary thromboprophylaxis in ambulatory cancer patients. 23 Two of these trials evaluated the benefit of primary thrombophylaxis in PC only. The PROSPECT-CONKO 004, 24 a prospective, randomized trial enrolled PC patients to receive chemotherapy plus enoxaparin or chemotherapy only. The primary end point was the incidence of VTE. Thromboprophylaxis was given through the first 12 weeks of treatment. Enoxaparin was associated with a relative risk reduction of 60% (15.1% VTE in the control group and 6.4% in the enoxaparin group) in VTE, with no increased risk of bleeding events between the two groups. However, no difference was detected between the two arms for the secondary end points of overall survival and progression-free survival. 24 An RCT of dalteparin in patients with advanced PC (the UK-FRAGEM study) 25 which randomized 123 patients with advanced PC to receive either gemcitabine with weight-adjusted dalteparin (GEM-WAD) for 12 weeks or gemcitabine (GEM) alone, indicated a significant reduction 
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Perl et al of all-type VTE. During the WAD treatment period, VTE was reduced from 23% to 3.4%, and all-type VTE throughout the follow-up period was reduced from 28% to 12%. "Lethal VTE" (events that clinically or postmortem were referred to as the cause of death) during the first 100 days was documented only in the control arm. There were fewer severe hemorrhagic complications in the GEM-WAD arm; however, trivial bleeding, mostly skin bruising and minor epistaxis, occurred in the GEM-WAD arm (9% vs 3%). Tumor control rates were similar between the two groups; median overall survival was 9.7 months for the GEM group and 8.7 months for the GEM-WAD group (P=0.841) and time to progression (TTP) was 5.3 months and 5.5 months, respectively (P=0.841). 25 
LMWH as primary thrombophylaxis in various malignancies, with PC as a subgroup
Several RCTs have evaluated LMWH concomitantly with chemotherapy in a variety of advanced solid malignancies. In the FAMOUS trial, 26 dalteparin was not found to have a significant impact on the risk of VTE compared with placebo in patients with advanced cancer, nor did it have an impact on survival. PC patients comprised 9.5% of the interventional group and 13% of the placebo group. 26 In the PROTECHT trial, 27 ambulatory patients were randomized to receive nadroparin or placebo for the duration of chemotherapy up to a maximum of 4 months. Among 1,150 patients, 53 (4.7%) had PC. In contrast to other trials, in the PROTECHT trial, 27 VTE rate was higher in the experimental group (8.3% vs 5.8%), possibly due to a small sample size. No data were reported on overall survival or TTP. 27 Another trial that randomized patients to receive nadroparin in addition to chemotherapy showed that there was no effect on survival or TTP. The median time to survival in the nadroparin and control arms was 8 months and 10.4 months, respectively. TTP in the nadroparin group was 5.7 months vs 6.7 months in the control group. 28 On the contrary, Klerk et al 29 showed that a brief course of nadroparin had a favorable impact on survival in patients with advanced tumors. In this trial, patients were assigned to receive nadroparin or placebo for 6 weeks during the beginning of their chemotherapy course. PC patients comprised 5% of the study's sample. The survival benefit was greater in patients with an expected survival of ≥6 months at enrollment, with a hazard ratio of 0.61 (95% confidence interval [CI]: 0.42-0.89), compared to a hazard ratio of 0.82 (95% CI: 0.51-1.29) in patients with life expectancy <6 months. 29 In the SAVE ONCO trial, 30 3,212 patients with solid tumors were randomized to receive semuloparin, an ultra-LMWH, or placebo with the chemotherapy regimen, until a change of the chemotherapy occurred; 8% of the patients had PC. Semuloparin was associated with a reduction in the risk of deep vein thrombosis (DVT) and fatal and nonfatal PE for the entire study population. In the PC subgroup, VTEs were reduced from 10.9% to 2.4% in the semuloparin group. Semuloparin did not influence the overall survival of all cancer types. 30 A meta-analysis of all randomized trials performed by our group evaluated the impact of prophylactic LMWH on preventing VTE as 
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Optimal management of VTE in pancreatic cancer well as the impact on survival. 31 We assessed the risk for DVT and PE; LMWH significantly reduced symptomatic DVT (relative risk [RR]: 0.35; 95% CI: 0.21-0.61) and PE (RR: 0.49; 95% CI: 0.25-071). In a subgroup of patients with PC, a pronounced effect of LMWH on VTE reduction has been documented (RR: 0.31; 95% CI: 0.18-0.55).The risk of major bleeding was not significantly increased. Our meta-analysis did not depict a survival advantage; however, in some of the included studies in an individual subgroup analysis, the group of patients with better prognosis experienced superior survival 26, 29 Current guidelines and recommendations
The American Society of Clinical Oncology, 32 the National Comprehensive Cancer Network, 33 and the ESMO 34 have developed guidelines for VTE prophylaxis in patients with cancer. The primary goal of thromboprophylaxis is VTE prevention, including PE and early death resulting from these complications. All guidelines recommend the use of prophylactic anticoagulation in hospitalized cancer patients unless contraindicated. All guidelines do not support routine primary thromboprophylaxis for ambulatory cancer patients outside clinical trials. Thromboprophylaxis may be considered in high-risk patients with a Khorana score ≥3. The Khorana score is a validated risk score used to identify patients at risk of VTE during chemotherapeutic treatment. It comprises patient characteristics such as cancer type and prechemotherapy blood counts. PC grants the patients with an additional two points, translating into a very high risk for VTE from the time of diagnosis. 6 Based on current guidelines, anticoagulation should not be used to improve survival in cancer patients in the absence of other indications.
Conclusion
VTE is a notable complication of cancer and cancer treatment, which causes considerable morbidity and mortality. As hospitalized and surgical patients with cancer are at higher risk for VTE, thrombophylaxis should be considered in this setting. Nevertheless, its role in ambulatory patients remains to be elucidated. PC patients are a unique subgroup of patients, due to relatively aggressive biological traits such as high incidence of VTE, hence making this therapeutic option more appealing. Most trials show a significant reduction of VTE in PC without a great risk of major bleeding. While the role of primary thrombophylaxis in cancer patients remains unclear, future studies, some of which are ongoing, might shed a light on its impact in the subset of the highly thrombogenic PC. The use of surrogate predictive biomarkers such as circulating tissue factor-bearing microparticles, as seen in the MicroTec trial, 13 may further optimize our understanding for the finest patient selection for this treatment.
Disclosure
The authors report no conflicts of interest in this work.
